2679 Results for "

endoscopic response

" in MedChemExpress (MCE) Product Catalog:

Products (2679)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

669

ML385

669 Publications Verification

Cat. No.: HY-100523

CAS No.: 846557-71-9

Purity: 99.96%

Target:

Keap1-Nrf2 Ferroptosis Apoptosis mTOR

Research Areas:

Cardiovascular Disease Cancer

ML385 is a potent and selective Nrf2 inhibitor with an IC₅₀ of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

223

Cyclosporin A

223 Cited Publications

Cat. No.: HY-B0579

CAS No.: 59865-13-3

Synonyms: Cyclosporine A; Ciclosporin A; CsA

Category:

Natural Products Microorganisms Anti-aging Disease Research Fields Inflammation/Immunology Cancer

Target:

Molecular Glues Complement System Antibiotic Cyclophilin

Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC₅₀ of 5 nM . Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

105

Tofacitinib

105 Cited Publications

Cat. No.: HY-40354

CAS No.: 477600-75-2

Synonyms: Tasocitinib; CP-690550

Target:

JAK STAT NF-κB

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

105

Tofacitinib citrate

105 Cited Publications

Cat. No.: HY-40354A

CAS No.: 540737-29-9

Synonyms: Tasocitinib citrate; CP-690550 citrate

Target:

JAK STAT NF-κB

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .

Compare